- In the CXO Talks podcast, PharmaShots spoke with Ali Jannati, Director of Cognitive Science at Linus Health. Ali eloquently highlighted Linus’ journey to becoming a leader in digital brain health through its innovative digital cognitive assessment platform
- He emphasized the importance of digital biomarkers in evaluating brain function by capturing subtle nuances and response latencies, which provide valuable insights. These biomarkers play a critical role in the early detection of mild cognitive impairment, which can progress into serious neurodegenerative conditions
- Ali also discussed the recent AD/PD conference, where Linus presented two posters from separate clinical studies. These studies evaluated Linus’ digital health solutions for identifying early indicators of cognitive and motor impairment
About the Author:
Ali Jannati
Ali is a physician-neuroscientist with 18+ years of research and clinical experience in cognitive neuroscience, neurology, neuromodulation, and digital health. As Director of Cognitive Science at Linus Health, Ali oversees the medical and neuroscientific aspects of the design, validation, scoring, and interpretation of our ML-enabled digital cognitive assessments (DCAs) and contributes to the development of related patents and drafting of our peer-reviewed publications. Further, Ali leads the design and implementation of clinical studies investigating the clinical validity, feasibility, and utility of the DCAs developed by Linus Health for the early detection of Alzheimer’s disease and related dementias (ADRD). Ali leads the development of Linus’ clinical decision support rules and recommendations for the diagnosis and management of patients with ADRD.
Related Post: CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots
